Clinically determined type of 18 F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer

Jae Uk Chong, Ho Kyoung Hwang, Jin Ho Lee, Mijin Yun, Chang Moo Kang, Woo Jung Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer. Methods: Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar 18 FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower 18 FDG uptake than that of renal calyx was regarded as Non-K type. Results: A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8%). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19-9 (P = 0.007), maximum standard uptake value (SUV max ,P<0.001), metabolic tumor volume (MTV 2.5 , P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior diseasefree survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012). Conclusions; Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.

Original languageEnglish
Article numbere0172606
JournalPloS one
Volume12
Issue number2
DOIs
Publication statusPublished - 2017 Feb

Fingerprint

2-deoxyglucose
pancreatic neoplasms
Deoxyglucose
Pancreatic Neoplasms
Positron emission tomography
Tumors
positron-emission tomography
kidneys
uptake mechanisms
Positron-Emission Tomography
Kidney
neoplasms
calyx
Chemotherapy
Neoplasms
Neoadjuvant Therapy
Kidney Neoplasms
glycolysis
Glycolysis
resection

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chong, Jae Uk ; Hwang, Ho Kyoung ; Lee, Jin Ho ; Yun, Mijin ; Kang, Chang Moo ; Lee, Woo Jung. / Clinically determined type of 18 F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer In: PloS one. 2017 ; Vol. 12, No. 2.
@article{fe80e0ae37604f7c8f7eef02ba9bb57e,
title = "Clinically determined type of 18 F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer",
abstract = "Purpose: To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer. Methods: Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar 18 FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower 18 FDG uptake than that of renal calyx was regarded as Non-K type. Results: A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2{\%}), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8{\%}). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19-9 (P = 0.007), maximum standard uptake value (SUV max ,P<0.001), metabolic tumor volume (MTV 2.5 , P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior diseasefree survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012). Conclusions; Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.",
author = "Chong, {Jae Uk} and Hwang, {Ho Kyoung} and Lee, {Jin Ho} and Mijin Yun and Kang, {Chang Moo} and Lee, {Woo Jung}",
year = "2017",
month = "2",
doi = "10.1371/journal.pone.0172606",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

Clinically determined type of 18 F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer . / Chong, Jae Uk; Hwang, Ho Kyoung; Lee, Jin Ho; Yun, Mijin; Kang, Chang Moo; Lee, Woo Jung.

In: PloS one, Vol. 12, No. 2, e0172606, 02.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinically determined type of 18 F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer

AU - Chong, Jae Uk

AU - Hwang, Ho Kyoung

AU - Lee, Jin Ho

AU - Yun, Mijin

AU - Kang, Chang Moo

AU - Lee, Woo Jung

PY - 2017/2

Y1 - 2017/2

N2 - Purpose: To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer. Methods: Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar 18 FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower 18 FDG uptake than that of renal calyx was regarded as Non-K type. Results: A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8%). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19-9 (P = 0.007), maximum standard uptake value (SUV max ,P<0.001), metabolic tumor volume (MTV 2.5 , P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior diseasefree survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012). Conclusions; Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.

AB - Purpose: To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer. Methods: Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar 18 FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower 18 FDG uptake than that of renal calyx was regarded as Non-K type. Results: A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8%). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19-9 (P = 0.007), maximum standard uptake value (SUV max ,P<0.001), metabolic tumor volume (MTV 2.5 , P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior diseasefree survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012). Conclusions; Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85013874355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013874355&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0172606

DO - 10.1371/journal.pone.0172606

M3 - Article

C2 - 28235029

AN - SCOPUS:85013874355

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0172606

ER -